Gitana Bradauskaite, MD
Internal Medicine · Philadelphia, PANPI 1902951304
Payments from drug & device makers
Across 244 payments — averaging $38.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- AstraZeneca$1K
- Vifor Pharma, Inc.$1K
- Bayer$929
- Ardelyx, Inc.$362
- Amgen$341
- plus $3K from 24 others
What the payments were for
- Consulting fees$2,25024%
- Speaking & faculty fees$4004%
- Travel & lodging$350%
- Food & beverage$6,63471%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 7 | $2,518 |
| AstraZeneca(2 entities) | 39 | $1,176 |
| Vifor Pharma, Inc. | 35 | $1,015 |
| Bayer | 21 | $929 |
| Ardelyx, Inc. | 13 | $362 |
| Amgen | 14 | $341 |
| Novartis | 14 | $316 |
| Akebia Therapeutics Inc | 10 | $296 |
| ANI Pharmaceuticals, Inc. | 13 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $236 |
| Aurinia Pharma U.S., Inc. | 13 | $234 |
| Veloxis Pharmaceuticals, Inc. | 5 | $223 |
| Sanofi | 5 | $194 |
| Mallinckrodt Enterprises LLC | 4 | $166 |
| Mallinckrodt Hospital Products Inc. | 5 | $142 |
| GSK | 6 | $131 |
| Johnson & Johnson | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $120 |
| Fresenius USA Marketing, Inc. | 6 | $115 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| Travere Therapeutics, Inc. | 5 | $77 |
| Boehringer Ingelheim | 4 | $69 |
| Merck | 2 | $48 |
| Apellis Pharmaceuticals, Inc. | 2 | $40 |
| Chiesi USA, Inc. | 2 | $39 |
| Baxter Healthcare | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Oxford Immunotec USA Inc | 1 | $25 |
| Cormedix Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$2,372
- Kerendia$570
- Veltassa$233
- SOLIRIS$150
- INVOKANA$125
- LOKELMA$121
- Envarsus$120
- THYMOGLOBULIN$120
- LIVTENCITY$119
- Vafseo$112
How this compares
$9,408 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 138 | $115,067 |
| Cinacalcet Hcl | 393 | $103,357 |
| EliquisApixaban | 108 | $69,006 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $47,164 |
| VeltassaPatiromer Calcium Sorbitex | 32 | $32,186 |
| TradjentaLinagliptin | 53 | $26,711 |
| Envarsus XrTacrolimus | 28 | $21,341 |
| Valganciclovir Hcl | 158 | $17,158 |
| ZenpepLipase/Protease/Amylase | 12 | $14,695 |
| Tacrolimus | 95 | $13,071 |
| FarxigaDapagliflozin Propanediol | 19 | $10,765 |
| EntrestoSacubitril/Valsartan | 15 | $9,992 |
| Nifedipine ErNifedipine | 681 | $9,646 |
| Atovaquone | 19 | $9,626 |
| VascepaIcosapent Ethyl | 13 | $4,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $1,176 | $125,832157 claims |
| Boehringer IngelheimTradjenta | $69 | $26,71153 claims |
| NovartisEntresto | $316 | $9,99215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Walter KraftPhiladelphia$3.7M
- Daniel RaderPhiladelphia$3.3M
- Archna BajajPhiladelphia$2.9M
- Gary YeomanPhiladelphia$2.4M
- Melina MarmarelisPhiladelphia$2.1M
- Adam WaxmanPhiladelphia$894K
- Donna GavaronePhiladelphia$728K
- Eyob FeyssaPhiladelphia$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.